LLY

749.3

-0.7%↓

JNJ

177.72

-0.2%↓

ABBV

216.91

-0.64%↓

UNH

348.68

-1.2%↓

AZN

78.03

-1.9%↓

LLY

749.3

-0.7%↓

JNJ

177.72

-0.2%↓

ABBV

216.91

-0.64%↓

UNH

348.68

-1.2%↓

AZN

78.03

-1.9%↓

LLY

749.3

-0.7%↓

JNJ

177.72

-0.2%↓

ABBV

216.91

-0.64%↓

UNH

348.68

-1.2%↓

AZN

78.03

-1.9%↓

LLY

749.3

-0.7%↓

JNJ

177.72

-0.2%↓

ABBV

216.91

-0.64%↓

UNH

348.68

-1.2%↓

AZN

78.03

-1.9%↓

LLY

749.3

-0.7%↓

JNJ

177.72

-0.2%↓

ABBV

216.91

-0.64%↓

UNH

348.68

-1.2%↓

AZN

78.03

-1.9%↓

Search

BioMarin Pharmaceutical Inc

Cerrado

SectorSanidad

53.17 -1.74

Resumen

Variación precio

24h

Actual

Mínimo

52.91

Máximo

54.23

Métricas clave

By Trading Economics

Ingresos

241M

426M

Ventas

80M

825M

P/B

Media del Sector

16.631

35.664

BPA

1.44

Margen de beneficios

51.637

Empleados

3,040

EBITDA

95M

319M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+82.27% upside

Dividendos

By Dow Jones

Próximas Ganancias

28 oct 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-740M

11B

Apertura anterior

54.91

Cierre anterior

53.17

Noticias sobre sentimiento de mercado

By Acuity

100%

0%

356 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

BioMarin Pharmaceutical Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

12 sept 2025, 22:41 UTC

Principales Movimientos del Mercado

GlucoTrack Stock Falls on Plans to Sell $3 Million Note

12 sept 2025, 16:04 UTC

Principales Movimientos del Mercado

Upexi Shares Climb on Solana Gains

14 sept 2025, 23:48 UTC

Charlas de Mercado

Oil Futures Mixed Amid Divergent Signals -- Market Talk

14 sept 2025, 23:41 UTC

Charlas de Mercado

Gold Edges Lower on Likely Technical Correction -- Market Talk

14 sept 2025, 23:38 UTC

Charlas de Mercado

China's Economic Activity Data May Continue Reflecting Slowdown -- Market Talk

14 sept 2025, 23:13 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

14 sept 2025, 23:13 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

14 sept 2025, 23:13 UTC

Charlas de Mercado

Infratil May Need to Be More Aggressive With Asset Sales -- Market Talk

14 sept 2025, 23:13 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

14 sept 2025, 23:04 UTC

Charlas de Mercado

Aristocrat's Interactive Unit Appears in Safe Hands -- Market Talk

13 sept 2025, 08:20 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

12 sept 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

12 sept 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

12 sept 2025, 20:09 UTC

Ganancias

Correction to Opendoor Is Sliding. Don't Call It a Meme Stock, Says New Chairman. -- Barrons.com

12 sept 2025, 19:23 UTC

Charlas de Mercado

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12 sept 2025, 19:16 UTC

Charlas de Mercado

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12 sept 2025, 19:03 UTC

Charlas de Mercado

Natural Gas Futures Held Back By Plump Inventories -- Market Talk

12 sept 2025, 18:59 UTC

Charlas de Mercado

Dollar Pares Gains as Economy Keeps Showing Signs of Cooling -- Market Talk

12 sept 2025, 18:38 UTC

Charlas de Mercado
Ganancias

Adobe Seen Reaching Turning Point in AI Cycle -- Market Talk

12 sept 2025, 18:33 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises By 2 to 416 -- Market Talk

12 sept 2025, 18:22 UTC

Charlas de Mercado

Canada's Divergence With US On Capex Spending is 'Appalling' -- Market Talk

12 sept 2025, 16:56 UTC

Charlas de Mercado

Renewable Fuels Association Calls for Nationwide E15 Following WASDE -- Market Talk

12 sept 2025, 16:22 UTC

Ganancias

Adobe Earnings Were 'Solid.' Long-Term Growth Concerns Remain. -- Barrons.com

12 sept 2025, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

12 sept 2025, 16:19 UTC

Adquisiciones, fusiones, absorciones

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

12 sept 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

12 sept 2025, 16:11 UTC

Ganancias

Novartis Catches a 'Sell.' Goldman Sachs Says the Stock Is Overvalued. -- Barrons.com

12 sept 2025, 15:37 UTC

Charlas de Mercado

Gold Holds Near All-Time Highs Ahead of Fed Meeting Next Week -- Market Talk

12 sept 2025, 15:22 UTC

Charlas de Mercado

European Gas Lifted by Geopolitical Risks But Storage Levels Ease Supply Fears -- Market Talk

12 sept 2025, 15:07 UTC

Adquisiciones, fusiones, absorciones

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

Comparación entre iguales

Cambio de precio

BioMarin Pharmaceutical Inc previsión

Precio Objetivo

By TipRanks

82.27% repunte

Estimación a 12 Meses

Media 98.59 USD  82.27%

Máximo 122 USD

Mínimo 60 USD

De acuerdo con 24 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para BioMarin Pharmaceutical Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

24 ratings

20

Comprar

4

Mantener

0

Vender

Puntuación técnica

By Trading Central

59.405 / 62.19Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Very Strong Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

356 / 371 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura bajista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.
help-icon Live chat